CN105412500A - 乳腺癌术后防止复发的护理用中药组合物及其制备方法 - Google Patents
乳腺癌术后防止复发的护理用中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN105412500A CN105412500A CN201510905834.1A CN201510905834A CN105412500A CN 105412500 A CN105412500 A CN 105412500A CN 201510905834 A CN201510905834 A CN 201510905834A CN 105412500 A CN105412500 A CN 105412500A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- herba
- minute
- bacillus natto
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 78
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 78
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 230000000474 nursing effect Effects 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims description 20
- 230000002980 postoperative effect Effects 0.000 title abstract 3
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 26
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 26
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 23
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 22
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 39
- 241000628997 Flos Species 0.000 claims description 24
- 241000190633 Cordyceps Species 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 238000009835 boiling Methods 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- -1 decoct while stir Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 4
- 235000002566 Capsicum Nutrition 0.000 claims description 3
- 239000006002 Pepper Substances 0.000 claims description 3
- 235000016761 Piper aduncum Nutrition 0.000 claims description 3
- 235000017804 Piper guineense Nutrition 0.000 claims description 3
- 244000203593 Piper nigrum Species 0.000 claims description 3
- 235000008184 Piper nigrum Nutrition 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 241000208368 Euonymus alatus Species 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 240000006023 Trichosanthes kirilowii Species 0.000 abstract 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 201000008275 breast carcinoma Diseases 0.000 description 28
- 238000011282 treatment Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000000481 breast Anatomy 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 5
- 210000005075 mammary gland Anatomy 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241000222341 Polyporaceae Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010038944 Retracted nipple Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000003910 Baronia <angiosperm> Species 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 206010006189 Breast cancer in situ Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000033640 Hereditary breast cancer Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 241000382362 Persicaria tinctoria Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004215 spore Anatomy 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000009306 yunnan baiyao Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种乳腺癌术后防止复发的护理用中药组合物,取下述重量配比的主要原料制备而成:草河车2-4份,木灵芝4-12份,车前草5-12份,娄仁泥9-18份,半枝莲6-15份,鬼箭羽3-9份,金银花4-6份,冬虫夏草3-9份,肉桂2-6份(优选的,3-5份,优选的,4份),纳豆菌0.3-1.0份,青黛3.5-8份。本发明所选材料均为传统中药材,无副作用,且药源易得,药材成本低廉,对治疗乳腺癌、肝癌、胃癌有很好的疗效。
Description
技术领域
本发明涉及中医中药领域,特别是涉及乳腺癌术后防止复发的护理用中药组合物及其制备方法。
背景技术
女性乳腺是由皮肤、纤维组织、乳腺腺体和脂肪组成的,乳腺癌是发生在乳腺腺上皮组织的恶性肿瘤。乳腺癌中99%发生在女性,男性仅占1%。乳腺并不是维持人体生命活动的重要器官,原位乳腺癌并不致命;但由于乳腺癌细胞丧失了正常细胞的特性,细胞之间连接松散,容易脱落。癌细胞一旦脱落,游离的癌细胞可以随血液或淋巴液播散全身,形成转移,危及生命。目前乳腺癌已成为威胁女性身心健康的常见肿瘤。全球乳腺癌发病率自20世纪70年代末开始一直呈上升趋势。美国8名妇女一生中就会有1人患乳腺癌。中国不是乳腺癌的高发国家,但不宜乐观,近年我国乳腺癌发病率的增长速度却高出高发国家1~2个百分点。据国家癌症中心和卫生部疾病预防控制局2012年公布的2009年乳腺癌发病数据显示:全国肿瘤登记地区乳腺癌发病率位居女性恶性肿瘤的第1位,女性乳腺癌发病率(粗率)全国合计为42.55/10万,城市为51.91/10万,农村为23.12/10万。乳腺癌已成为当前社会的重大公共卫生问题。自20世纪90年代全球乳腺癌死亡率呈现出下降趋势;究其原因,一是乳腺癌筛查工作的开展,使早期病例的比例增加;二是乳腺癌综合治疗的开展,提高了疗效。乳腺癌已成为疗效最佳的实体肿瘤之一。
病因:乳腺癌的病因尚未完全清楚,研究发现乳腺癌的发病存在一定的规律性,具有乳腺癌高危因素的女性容易患乳腺癌。所谓高危因素是指与乳腺癌发病有关的各种危险因素,而大多数乳腺癌患者都具有的危险因素就称为乳腺癌的高危因素。据中国肿瘤登记年报显示:女性乳腺癌年龄别发病率0~24岁年龄段处较低水平,25岁后逐渐上升,50~54岁组达到高峰,55岁以后逐渐下降。乳腺癌家族史是乳腺癌发生的危险因素,所谓家族史是指一级亲属(母亲,女儿,姐妹)中有乳腺癌患者。近年发现乳腺腺体致密也成为乳腺癌的危险因素。乳腺癌的危险因素还有月经初潮早(<12岁),绝经迟(>55岁);未婚,未育,晚育,未哺乳;患乳腺良性疾病未及时诊治;经医院活检(活组织检查)证实患有乳腺非典型增生;胸部接受过高剂量放射线的照射;长期服用外源性雌激素;绝经后肥胖;长期过量饮酒;以及携带与乳腺癌相关的突变基因。需要解释的是乳腺癌的易感基因欧、美国家做了大量研究,现已知的有BRCA-1、BRCA-2,还有p53、PTEN等,与这些基因突变相关的乳腺癌称为遗传性乳腺癌,占全部乳腺癌的5%~10%。具有以上若干项高危因素的女性并不一定患乳腺癌,只能说其患乳腺癌的风险比正常人高,中国妇女乳腺癌的发病率还是低的。
乳腺癌的外科手术包括乳腺和腋窝淋巴结两部分。乳腺手术有保留乳房手术(保乳手术)和全乳房切除术。腋窝淋巴结手术有前哨淋巴结活检和腋窝淋巴结清扫。前哨淋巴结活检是只切除前哨淋巴结,经检测前哨淋巴结转移再进行腋窝淋巴结清扫,也有人称之为保腋窝手术。保乳手术有严格的手术适应证,目前还做不到所有的乳腺癌患者都能进行保乳手术。对不适合保乳手术的乳腺癌患者还需要切除乳房,医生可以采用整形外科技术重建乳房。乳房重建可采用自体组织重建,也可采用假体重建。可以在切除肿瘤手术的同时进行乳房重建,也可在治疗结束后,各项复查结果正常时进行重建。进行乳房重建不会影响乳腺癌的整体治疗。
目前,乳腺癌术后防止复发的中药较为稀少,针对上述问题,有待进一步提高。
发明内容
针对现有技术的不足,本发明的目的之一是提供一种制备简单、服用方便、便于携带的乳腺癌术后防止复发的护理用中药组合物,该制剂疗效显著且无副作用,本发明的另一目的就是提供上述护理用中药组合物的制备方法。
本发明的上述目的是通过以下技术方案来实现的:
乳腺癌术后防止复发的护理用中药组合物,取下述重量配比的主要原料制备而成:草河车2-4份,木灵芝4-12份,车前草5-12份,积雪草9-18份,半枝莲6-15份,卫矛3-9份,金银花4-6份,冬虫夏草3-9份,肉桂2-6份(优选的,3-5份,优选的,4份),纳豆菌0.3-1.0份,青黛3.5-8份。
乳腺癌术后防止复发的护理用中药组合物,优选的方案为,取下述重量配比的主要原料制备而成:草河车2.5-3.5份,木灵芝7-9份,车前草7-10份,积雪草12-15份,半枝莲9-12份,卫矛5-7份,金银花4.5-5.5份,冬虫夏草5-7份,肉桂3-5份,纳豆菌0.5-0.8份,青黛5-7份。
乳腺癌术后防止复发的护理用中药组合物,更加优选的方案为,取下述重量配比的主要原料制备而成:草河车3份,木灵芝8份,车前草8份,积雪草13份,半枝莲10份,卫矛6份,金银花5份,冬虫夏草6份,肉桂4份,纳豆菌0.6份,青黛6份。
本发明还提供了将上述护理用中药组合物制成药学上可接受的口服液、粉剂或胶囊。
所述乳腺癌术后防止复发的护理用中药组合物口服液的制备方法是:
(1)将车前草和卫矛置于蒸笼上,蒸10-20分钟,转文火炒至五六成熟,喷上黄酒,静置2-4小时,继续炒至酥脆,研磨成细末过80-120目筛(优选90-110目筛,更加优选100目筛);
(2)将金银花置于砂锅内,加入金银花重量5-8倍的蜂蜜水,煮沸后转文火煎煮33-46分钟,过滤,滤液待用;
(3)将草河车、木灵芝、积雪草、半枝莲、冬虫夏草和肉桂置于花椒水中浸泡50-70分钟,置于瓦片上小火慢烘4-8分钟(优选5-7分钟,更加优选6分钟),搓成细末过筛待用;
(4)将步骤(1)与步骤(3)所得药物置于步骤(2)所得滤液中,一边煎煮一边搅拌,使药物充分的混匀,待煮5-15分钟后将温度冷却至室温,加入纳豆菌和青黛,静置4-6小时,得上清液,高温灭菌,封装即得口服液。
上述护理用中药组合物口服液的制备方法,步骤(4)待煮8-13分钟后将温度冷却至室温,加入纳豆菌和青黛,静置4.5-5.5小时(优选待煮10分钟后将温度冷却至室温,加入纳豆菌和青黛,静置5小时)。
服用方法:每次服用5-10ml,每天2-3次,用60℃左右的温开水冲服,3天一个疗程。
所述乳腺癌术后防止复发的护理用中药组合物粉剂的制备方法是:
(1)将草河车、木灵芝、车前草、积雪草、半枝莲、卫矛、金银花、冬虫夏草和肉桂洗净,沥干水分,用原料药总重量2-4倍的高粱酒拌匀,浸泡34-57分钟,烘干研磨成细末待用;
(2)将纳豆菌和青黛置于透明的玻璃容器内,加入20-40℃的蜂蜜水,充分搅拌均匀待用;
(3)将步骤(1)与(2)所得物混匀,一边煎煮一边搅拌成稠膏,将稠膏用小火烘制10-20分钟,灭菌分装即得粉剂。
上述护理用中药组合物粉剂的制备方法,步骤(1)用原料药总重量2.5-3.5倍的高粱酒拌匀,浸泡40-50分钟(优选用原料药总重量3倍的高粱酒拌匀,浸泡45分钟)。
使用方法:每次用60℃左右的温开水冲服,3g/次,每天3次,饭后半小时服用,2天一个疗程。
所述乳腺癌术后防止复发的护理用中药组合物胶囊的制备方法是:
(1)将草河车、木灵芝、车前草、积雪草、半枝莲、卫矛、金银花、冬虫夏草和肉桂洗净,沥干水分,用原料药总重量2-4倍的高粱酒拌匀,浸泡34-57分钟,烘干研磨成细末待用;
(2)将纳豆菌和青黛置于透明的玻璃容器内,加入20-40℃的蜂蜜水,充分搅拌均匀待用;
(3)将步骤(1)与(2)所得物混匀,一边煎煮一边搅拌成稠膏,将稠膏用小火烘制10-20分钟,按照胶囊的加工工艺分装制备成胶囊。
服用方法:每天3次,每次2-4粒,用35℃左右的温开水送服,饭后半小时服用,2天一个疗程。
本发明所用主要中药原料的药理如下:
草河车:别名:华重楼、七叶楼、铁灯台、草河车、蚤休、重楼、金盘托荔枝、草河车。性味:苦、凉。小毒。归经:归心经、肝经、肺经、胃经、大肠经。功能:败毒抗癌、消肿止痛、清热定惊、镇咳平喘。主治:治痈肿肺痨久咳、跌打损伤、蛇虫咬伤、淋巴结核、骨髓炎等症,是云南白药的主要成分之一。
车前草:味甘,性寒。归经:归肝、肾、膀胱经。功效:清热,利尿,祛痰,凉血,解毒。主治:用于水肿尿少,热淋涩痛,暑湿泻痢,痰热咳嗽,吐血衄血,痈肿疮毒。
木灵芝:木灵芝是灵芝的其中一个别名,“木灵芝”不是灵芝科中的标准文献名称的定义,而是民间一种不规范的称呼。灵芝科的品种繁多,目前,全世界已发现的灵芝科的品种有两百多种,而在中国发现有一百多种。甘,平。归心、肺、肝、肾经。主治虚劳、咳嗽、气喘、失眠、消化不良,恶性肿瘤等。动物药理表明实验:灵芝对神经系统有抑制作用,循环系统有降压和加强心脏收缩力的作用,对呼吸系统有祛痰作用,此外,还有护肝、提高免疫功能,抗菌等作用。
积雪草:清热利湿,消肿解毒。治痧气腹痛,暑泻,痢疾,湿热黄疸,砂淋,血淋,吐、衄、咳血,目赤,喉肿,风疹,疥癣,疔痈肿毒,跌打损伤。积雪草适用于各种肤质,其幼芽的水提取物具有抗菌消炎的作用,其属双子叶植物伞形科,能消肿解毒祛脓疮。
半枝莲:半支莲全草入药,具有清热解毒、活血祛瘀、消肿止痛、抗癌等功能。性寒味酸,全草含多种维生素、微量元素及氨基酸等成分。有凉血解毒,散瘀止痛,消肿和清热利湿之功效,有清热解毒,活血化瘀,消肿止痛,抗癌之功效;治阑尾炎、肝炎、胃痛、早期肝癌、肺癌、子宫颈癌、乳腺炎等;外用治痛疖疗,跌打肿痛等症。此药民间用量较大。
卫矛:鬼箭羽、鬼箭、六月凌、四面锋、蓖箕柴、四棱树,苦,寒。行血通经,散瘀止痛。用于经闭,症瘕,产后瘀滞腹痛,虫积腹痛,漆疮。
金银花:现代研究证明,金银花含有绿原酸、木犀草素苷等药理活性成分,对溶血性链球菌、金黄葡萄球菌等多种致病菌及上呼吸道感染致病病毒等有较强的抑制力,另外还可增强免疫力、抗早孕、护肝、抗肿瘤、消炎、解热、止血(凝血)、抑制肠道吸收胆固醇等,其临床用途非常广泛,可与其它药物配伍用于治疗呼吸道感染、菌痢、急性泌尿系统感染、高血压等40余种病症。金银花性寒,味甘,入肺、心、胃经,具有清热解毒、抗炎、补虚疗风的功效,主治胀满下疾、温病发热,热毒痈疡和肿瘤等症。其对于头昏头晕、口干作渴、多汗烦闷、肠炎、菌痢、麻疹、肺炎、乙脑、流脑、急性乳腺炎、败血症、阑尾炎、皮肤感染、痈疽疔疮、丹毒、腮腺炎、化脓性扁桃体炎等病症均有一定疗效。
冬虫夏草:冬虫夏草又名虫草,是我国民间惯用的一种名贵滋补药材,其营养成分高于人参,可入药,也可食用,是上乘的佳肴,具有很高的营养价值。冬虫夏草可以增强机体的免疫力,滋补肺肾,对肺癌、肝癌等有明显的抑制作用。在临床上对肺虚久咳,气喘,肺结核咯血,盗汗,肾虚腰膝酸痛,阳痿遗精,神经衰弱及化疗、放疗后的红细胞下降都有疗效。
肉桂:补元阳,暖脾胃,除积冷,通血脉。治命门火衰,肢冷脉微,亡阳虚脱,腹痛泄泻,寒疝奔豚,腰膝冷痛,经闭症瘕,阴疽,流注,及虚阳浮越,上热下寒。
纳豆菌:纳豆芽孢杆菌是枯草芽孢杆菌的一个亚种,是一类好氧型、内生抗逆胞子的杆状细菌,自身没有致病性,只具有单层细胞外膜,能产生多种抗菌素和酶,具有广谱抗菌活性和极强的抗逆能力。在极端的条件下,还可以诱导产生抗逆性很强的内源胞子。孢子型纳豆菌是具有耐酸、耐热特性的有益菌,在胃酸下四小时存活率为100%,同时具有强力的病原菌抑制能力,是各种益菌当中,对环境耐受力最好可以直达小肠的菌种之一,口服后可改变人体肠道菌丛生态,帮助消化道机能正常化,以使排便顺畅,维持体内生理环保。产酸,调节肠道菌群,增强动物细胞免疫放应。并能生成多种蛋白酶(特别是碱性蛋白酶)、糖化酶、脂肪酶、淀粉酶,降解植物性饲料种某些复杂的碳水化合物,从而提高饲料的转化率。
青黛:为爵应酬科植物马蓝、蓼科植物蓼蓝、十字花科植物菘蓝的叶或茎叶经加工制得的干燥粉末、团块或颗粒。具清热解毒、凉血消斑,泻火定惊等作用,在古代亦常用于印染布匹、画眉等。主产于福建、云南、江苏等地。性味咸寒,有清热解毒,凉血消斑,泻火定惊等功效。其主要用于温病热盛,斑疹,吐血、咯血,咽痛口疮,小儿惊痫,疮肿,丹毒,蛇虫咬伤等。
本发明的技术优势主要体现在:
1.本发明药剂基于中医中药治疗的原理,是在研究了大量文献、药理工作和临床试验的基础上制成的,效果显著。
2.本药剂所选材料均为传统中药材,无副作用。
3.药材药源易得,成本低廉,不会给患者带来大的经济负担。
具体实施方式
实施例1乳腺癌术后防止复发的护理用中药组合物,取下述重量配比的主要原料制备而成(每份取20g):草河车2份,木灵芝4份,车前草5份,积雪草9份,半枝莲6份,鬼箭羽3份,金银花4份,冬虫夏草3份,肉桂2份,纳豆菌0.3份,青黛3.5份。
上述乳腺癌术后防止复发的护理用中药组合物口服液的制备方法为:
(1)将车前草和卫矛置于蒸笼上,蒸10分钟,转文火炒至五六成熟,喷上黄酒,静置2小时,继续炒至酥脆,研磨成细末过80目筛;
(2)将金银花置于砂锅内,加入金银花重量5倍的蜂蜜水,煮沸后转文火煎煮33分钟,过滤,滤液待用;
(3)将草河车、木灵芝、积雪草、半枝莲、冬虫夏草和肉桂置于花椒水中浸泡50分钟,置于瓦片上小火慢烘4分钟,搓成细末过筛待用;
(4)将步骤(1)与步骤(3)所得药物置于步骤(2)所得滤液中,一边煎煮一边搅拌,使药物充分的混匀,待煮5分钟后将温度冷却至室温,加入纳豆菌和青黛,静置4小时,得上清液,高温灭菌,封装即得口服液。
服用方法:每次服用5-10ml,每天2-3次,饭后半小时,用60℃左右的温开水冲服,3天一个疗程。
典型病例一:王XX,女,50岁,山东省烟台市莱阳市人,患者去年4月份绝经,绝经后左乳外上象限发现一质硬无痛性肿块,直径约2.1厘米,轻微活动,有刺痛感,当时以为是绝经后的正常现象,过了一段时间,肿块渐大、渐硬,出现乳头内陷并固定,左乳皮肤红、肿、热、痛,左乳头可挤出少量褐色液体,左腋下肿大淋巴结融合成团,约4×3×3厘米大小,质硬、界欠清、固定、无压痛,去医院检查,确诊为乳腺癌,家人非常的着急,也非常的担心,怕痊愈不了,也怕手术后再复发,来我院就诊,我院医生给其做了手术,并且开了本发明所得口服液治疗。
服用实施例1所得乳腺癌术后防止复发的护理用中药组合物口服液,15天后,患者感觉睡眠,吃饭都非常的规律,切饭量大增,继续服用5天,自感不适症状消失,而且术后愈合的非常的好,又继续服用15天,患者自感痊愈,可以正常的工作。
实施例2:乳腺癌术后防止复发的护理用中药组合物,取下述重量配比的主要原料制备而成(每份取20g):草河车3.5份,木灵芝9份,车前草10份,积雪草15份,半枝莲12份,卫矛7份,金银花5.5份,冬虫夏草7份,肉桂5份,纳豆菌0.8份。
上述乳腺癌术后防止复发的护理用中药组合物粉剂的制备方法为:
(1)将草河车、木灵芝、车前草、积雪草、半枝莲、卫矛、金银花、冬虫夏草和肉桂洗净,沥干水分,用原料药总重量2倍的高粱酒拌匀,浸泡34分钟,烘干研磨成细末待用;
(2)将纳豆菌和青黛置于透明的玻璃容器内,加入20℃的蜂蜜水,充分搅拌均匀待用;
(3)将步骤(1)与(2)所得物混匀,一边煎煮一边搅拌成稠膏,将稠膏用小火烘制10分钟,灭菌分装即得粉剂。
上述护理用中药组合物粉剂的制备方法,步骤(1)用原料药总重量2.5倍的高粱酒拌匀,浸泡40分钟。
使用方法:每次用60℃左右的温开水冲服,3g/次,每天3次,饭后半小时服用,2天一个疗程。
典型病例二:孙XX,女,28岁,山东省济南市长清人,一年前左乳外上象限发现一质硬无痛性肿块,直径约2.0厘米,轻微活动,当时以为刚给孩子戒奶,可能是有奶还没有回收,过了半月,肿块渐大、渐硬,半年前出现乳头内陷并固定,出现左乳皮肤红、肿、热、痛,左乳头可挤出少量褐色液体,左腋下肿大淋巴结融合成团,约4×3×3厘米大小,质硬、界欠清、固定、无压痛,去医院检查,确诊为乳腺癌,家人非常的着急,也非常的担心,怕痊愈不了,也怕手术后再复发,来我院就诊,我院医生给其做了手术,并且开了本发明所得粉剂治疗。
服用实施例2所得乳腺癌术后防止复发的护理用中药组合物粉剂,10天后,患者感觉睡眠,吃饭都非常的规律,切饭量大增,继续服用10天,自感不适症状消失,而且术后愈合的非常的好,又继续服用10天,患者自感痊愈,可以正常的工作。
实施例3:乳腺癌术后防止复发的护理用中药组合物,取下述重量配比的主要原料制备而成(每份取30g):草河车3份,木灵芝8份,车前草8份,积雪草13份,半枝莲10份,鬼箭羽6份,金银花5份,冬虫夏草6份,肉桂4份,纳豆菌0.6份,青黛6份。
上述乳腺癌术后防止复发的护理用中药组合物胶囊的制备方法为:
所述乳腺癌术后防止复发的护理用中药组合物胶囊的制备方法是:
(1)将草河车、木灵芝、车前草、积雪草、半枝莲、卫矛、金银花、冬虫夏草和肉桂洗净,沥干水分,用原料药总重量3倍的高粱酒拌匀,浸泡45分钟,烘干研磨成细末待用;
(2)将纳豆菌和青黛置于透明的玻璃容器内,加入30℃的蜂蜜水,充分搅拌均匀待用;
(3)将步骤(1)与(2)所得物混匀,一边煎煮一边搅拌成稠膏,将稠膏用小火烘制15分钟,按照胶囊的加工工艺分装制备成胶囊。
试验例:实施例3所得乳腺癌术后防止复发的护理用中药组合物胶囊的临床应用:2010年8月-2012年2月,筛选了200例患者,试验之前1周,对该人群进行连续观察,记录症状及变化,随机分为两组,实验组及对照组,实验组服用实施例3所得乳腺癌术后防止复发的护理用中药组合物胶囊,对照组服用其它药品(如赫赛汀、他莫昔芬等常规治疗乳腺癌防止复发的药物)。
服用方法:每天3次,每次2-4粒,用35℃左右的温开水送服,饭后半小时服用,2天一个疗程。
疗效情况判定标准:治愈:服用本品后,不适症状完全消失,精力及体力明显增强;有效:服用本品后,不适症状减轻或部分消失,精力及体力增强;无效:服用本品后,不适症状无变化或后期复发。其中,总有效率包括治愈率和有效率。结果如表1所示。
治疗效果:从表1可以看出,服用本发明乳腺癌术后防止复发的护理用中药组合物胶囊的治愈率高达81%,总有效率98%,无效率仅为2%;而服用其他治疗乳腺癌的药物的治愈率仅34%,总有效率86%,无效率高达14%,服用其他治疗乳腺癌的药物的总有效率相对也不低,但治愈率却较低并且无效率较高,可以看出:服用本发明乳腺癌术后防止复发的护理用中药组合物胶囊的效果明显优于服用其他治疗乳腺癌的药物。
从表2可以看出:实验组的各症状都在很大程度上得到了缓解,总之,该临床实验表明使用本发明乳腺癌术后防止复发的护理用中药组合物胶囊的给药组与口服西药其他治疗乳腺癌的药物的对照组相比,其疗效大幅度提高,且治愈率显著提升,并且复发率显著降低,真正解决病人的病痛。
Claims (9)
1.乳腺癌术后防止复发的护理用中药组合物,其特征在于:取下述重量配比的主要原料制备而成:草河车2-4份,木灵芝4-12份,车前草5-12份,积雪草9-18份,半枝莲6-15份,鬼箭羽3-9份,金银花4-6份,冬虫夏草3-9份,肉桂2-6份(优选的,3-5份,优选的,4份),纳豆菌0.3-1.0份,青黛3.5-8份。
2.根据权利要求1所述的乳腺癌术后防止复发的护理用中药组合物,其特征在于:取下述重量配比的主要原料制备而成:草河车2.5-3.5份,木灵芝7-9份,车前草7-10份,积雪草12-15份,半枝莲9-12份,鬼箭羽5-7份,金银花4.5-5.5份,冬虫夏草5-7份,肉桂3-5份,纳豆菌0.5-0.8份,青黛5-7份。
3.根据权利要求1所述的乳腺癌术后防止复发的护理用中药组合物,其特征在于:取下述重量配比的主要原料制备而成:草河车3份,木灵芝8份,车前草8份,积雪草13份,半枝莲10份,鬼箭羽6份,金银花5份,冬虫夏草6份,肉桂4份,纳豆菌0.6份,青黛6份。
4.根据权利要求1-3任一项所述的护理用中药组合物,其特征在于:可制成药学上可接受的口服液、粉剂或胶囊。
5.根据权利要求4所述的乳腺癌术后防止复发的护理用中药组合物口服液的制备方法,其特征在于:步骤如下:
(1)将车前草和鬼箭羽置于蒸笼上,蒸10-20分钟,转文火炒至五六成熟,喷上黄酒,静置2-4小时,继续炒至酥脆,研磨成细末过80-120目筛(优选90-110目筛,更加优选100目筛);
(2)将金银花置于砂锅内,加入金银花重量5-8倍的蜂蜜水,煮沸后转文火煎煮33-46分钟,过滤,滤液待用;
(3)将草河车、木灵芝、积雪草、半枝莲、冬虫夏草和肉桂置于花椒水中浸泡50-70分钟,置于瓦片上小火慢烘4-8分钟(优选5-7分钟,更加优选6分钟),搓成细末过筛待用;
(4)将步骤(1)与步骤(3)所得药物置于步骤(2)所得滤液中,一边煎煮一边搅拌,使药物充分的混匀,待煮5-15分钟后将温度冷却至室温,加入纳豆菌和青黛,静置4-6小时,得上清液,高温灭菌,封装即得口服液。
6.根据权利要求5所述的护理用中药组合物口服液的制备方法,其特征在于:步骤(4)待煮8-13分钟后将温度冷却至室温,加入纳豆菌和青黛,静置4.5-5.5小时(优选待煮10分钟后将温度冷却至室温,加入纳豆菌和青黛,静置5小时)。
7.根据权利要求4所述的乳腺癌术后防止复发的护理用中药组合物粉剂的制备方法,其特征在于:步骤如下:
(1)将草河车、木灵芝、车前草、积雪草、半枝莲、鬼箭羽、金银花、冬虫夏草和肉桂洗净,沥干水分,用原料药总重量2-4倍的高粱酒拌匀,浸泡34-57分钟,烘干研磨成细末待用;
(2)将纳豆菌和青黛置于透明的玻璃容器内,加入20-40℃的蜂蜜水,充分搅拌均匀待用;
(3)将步骤(1)与(2)所得物混匀,一边煎煮一边搅拌成稠膏,将稠膏用小火烘制10-20分钟,灭菌分装即得粉剂。
8.根据权利要求7所述的护理用中药组合物粉剂的制备方法,其特征在于:步骤(1)用原料药总重量2.5-3.5倍的高粱酒拌匀,浸泡40-50分钟(优选用原料药总重量3倍的高粱酒拌匀,浸泡45分钟)。
9.根据权利要求4所述的乳腺癌术后防止复发的护理用中药组合物胶囊的制备方法,其特征在于:步骤如下:
(1)将草河车、木灵芝、车前草、积雪草、半枝莲、鬼箭羽、金银花、冬虫夏草和肉桂洗净,沥干水分,用原料药总重量2-4倍的高粱酒拌匀,浸泡34-57分钟,烘干研磨成细末待用;
(2)将纳豆菌和青黛置于透明的玻璃容器内,加入20-40℃的蜂蜜水,充分搅拌均匀待用;
(3)将步骤(1)与(2)所得物混匀,一边煎煮一边搅拌成稠膏,将稠膏用小火烘制10-20分钟,按照胶囊的加工工艺分装制备成胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510905834.1A CN105412500A (zh) | 2015-12-10 | 2015-12-10 | 乳腺癌术后防止复发的护理用中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510905834.1A CN105412500A (zh) | 2015-12-10 | 2015-12-10 | 乳腺癌术后防止复发的护理用中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105412500A true CN105412500A (zh) | 2016-03-23 |
Family
ID=55491347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510905834.1A Pending CN105412500A (zh) | 2015-12-10 | 2015-12-10 | 乳腺癌术后防止复发的护理用中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105412500A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679892A (zh) * | 2005-01-12 | 2005-10-12 | 胡仕敏 | 治疗癌症的口服液及其生产方法 |
-
2015
- 2015-12-10 CN CN201510905834.1A patent/CN105412500A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679892A (zh) * | 2005-01-12 | 2005-10-12 | 胡仕敏 | 治疗癌症的口服液及其生产方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103877287B (zh) | 一种治疗乳腺癌的药物及制备方法 | |
CN103893738B (zh) | 一种抑制肿瘤生长中药组合物及其制备方法 | |
CN103638361B (zh) | 一种治疗咳嗽的药物及其制备方法 | |
CN110339276B (zh) | 一种治疗消化道肿瘤的扶正清解中药及其制备方法 | |
CN104784632A (zh) | 用于缓解呼吸道黏膜充血水肿症状的中药药丸及制备方法 | |
CN104001045A (zh) | 一种用于治疗犬肺炎的药物及其制备方法 | |
CN104771462A (zh) | 一种治疗慢性支气管炎的中药及其制备方法 | |
CN104306867A (zh) | 一种治疗病毒性心肌炎的中药制剂及制备方法 | |
CN103877457B (zh) | 一种治疗肾结石的中药制剂及制备方法 | |
CN105412500A (zh) | 乳腺癌术后防止复发的护理用中药组合物及其制备方法 | |
CN104258032A (zh) | 一种治疗胃癌的中药组合物 | |
CN104984187A (zh) | 一种用于治疗慢性胃炎的中药 | |
CN105012789A (zh) | 治疗宫颈癌的组合物及其制备方法 | |
CN104721740A (zh) | 一种治疗淋巴结核、淋巴瘤的中药组合物 | |
CN104623451A (zh) | 一种治疗乳腺癌的中药组合物 | |
CN116077603A (zh) | 一种治疗慢性萎缩性胃炎的中药组合物及其制备方法 | |
CN104208380A (zh) | 一种用于治疗败血症的胶囊及制备方法 | |
CN104606537A (zh) | 改善化疗所致心肌缺血损伤的益气养血药膳及制备方法 | |
CN102698221B (zh) | 一种治疗急性胆囊炎的中药、制备方法及应用 | |
CN109276691A (zh) | 一种用于治疗急性胰腺炎的中药 | |
CN109125682A (zh) | 一种用于治疗急性胰腺炎的中药 | |
CN109381683A (zh) | 一种用于治疗急性胰腺炎的中药 | |
CN109381681A (zh) | 一种用于治疗急性胰腺炎的中药 | |
CN107812165A (zh) | 一种用于治疗急性胰腺炎的中药 | |
CN105853637A (zh) | 对放化疗具有增效作用的中药组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160323 |